ESMO 2019 Prostate Cancer - Results from #20

Viewing 21-40 of 63 articles

ESMO 2019: Patient-Reported Outcomes From TITAN: A Phase 3, Randomized, Double-Blind Study of Apalutamide Versus Placebo Added to Androgen Deprivation Therapy in Patients With Metastatic Castration-Sensitive Prostate Cancer

ESMO 2019: Exploratory Analyses of Metastatic Site and Number in the STAMPEDE “M1|RT Comparison”

ESMO 2019: Central, Prospective Detection of Homologous Recombination Repair Gene Mutations (HRRm) in Tumour Tissue from >4000 Men with mCRPC Screened for the PROfound Study

ESMO 2019: Introduction to Genomic Tumor Board Educational Session

ESMO 2019: Health-Related Quality of Life in a Randomized Phase 3 Trial of Enzalutamide with Standard First Line Therapy for Metastatic Hormone-Sensitive Prostate Cancer: ENZAMET, ANZUP-led, International, Co-Operative Group Trial

ESMO 2019: Setting up Genomic Tumor Boards – What Can Be Done and What Needs to Be Done

ESMO 2019: Homogenizing Genomic Reports: What Clinicians Need to Know

ESMO 2019: How Genomic Data Can Result in the Better Delivery of Prostate Cancer Care and Research

ESMO 2019: Docetaxel for Hormone-Naïve Prostate Cancer: Results from Long-term Follow-up of Non-metastatic Patients in the STAMPEDE Randomised Trial - A Medical Oncologist's Perspective

ESMO 2019: Preliminary Results of a Phase I/II Dose-escalation Study of Fractionated Dose 177Lu-PSMA-617 for Progressive mCRPC

ESMO 2019: Preliminary Results of A Phase I/II Dose-Escalation Study of Fractionated Dose 177Lu-PSMA-617 for Progressive Metastatic Castration Resistant Prostate Cancer - A Medical Oncologist's Perspective

ESMO 2019: Docetaxel for Hormone-naïve Prostate Cancer: Results from Long-term Follow-up of Non-metastatic (M0) Patients in the STAMPEDE Randomized Trial

ESMO 2019: Pembrolizumab with Enzalutamide in mCRPC: Examination of Tumor Infiltrating Immune Cells and Fecal Microbiota, A Phase II Study - A Medical Oncologist's Perspective

ESMO 2019: Phase II Study of Pembrolizumab with Enzalutamide in Metastatic Castration-Resistant Prostate Cancer: 30 Patient Expansion with Examination of Tumor Infiltrating Immune Cells and Fecal Microbiota

ESMO 2019: Efficacy and Safety of Nivolumab in Combination With Docetaxel in Men With Metastatic Castration-Resistant Prostate Cancer in CheckMate 9KD - Medical Oncologist Perspective

Clovis Oncology Highlights Rubraca® (rucaparib) Updated Data from the Ongoing TRITON2 Clinical Trial in Patients with Metastatic Castration-Resistant Prostate Cancer and Exploratory and Integrated Analyses in Recurrent Ovarian Cancer at the ESMO Congress

ESMO 2019: Preliminary Results from the TRITON2 Study of Rucaparib in Patients with DNA Damage Repair (DDR)-deficient Metastatic Castration-resistant Prostate Cancer (mCRPC): Updated Analyses

ESMO 2019: Central, Prospective Detection of Homologous Recombination Repair Gene Mutations in Tumor Tissue from >4000 Men with mCRPC Screened for the PROfound Study

ESMO 2019: Preliminary Results from the TRITON2 Study of Rucaparib in Patients with DNA Damage Repair-deficient mCRPC: Updated Analyses

ESMO 2019: Invited Discussant: (LBA50, 845PD, 846PD and 847PD) Genitourinary Tumors, Prostate

1
2
3
4